Last Updated : April 18, 2024
Details
FilesGeneric Name:
bimekizumab
Project Status:
Active
Therapeutic Area:
Psoriatic arthritis
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0803-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 23, 2023 |
|---|---|
| Call for patient/clinician input closed | October 17, 2023 |
| Clarification: - Patient input submission received from the ACE, CPN, ASC, CAPA, CAPP, CSA, and CJ | |
| Submission received | October 05, 2023 |
| Submission accepted | October 20, 2023 |
| Review initiated | October 23, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | January 18, 2024 |
| Deadline for sponsors comments | January 30, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | March 14, 2024 |
| Expert committee meeting (initial) | March 27, 2024 |
| Draft recommendation issued to sponsor | April 10, 2024 |
| Draft recommendation posted for stakeholder feedback | April 18, 2024 |
| End of feedback period | May 03, 2024 |
Files
Last Updated : April 18, 2024